Assessment of Response to Neoadjuvant Chemotherapy with Single and Dual HER2 Blockade in HER2-Positive Breast Cancers: A Single-Center Experience
Beurteilung des Ansprechens auf neoadjuvante Chemotherapie mit Single- und Dual-HER2-Blockade bei HER2-positivem Mammakarzinom: Single-Center-Erfahrung
Indian Journal of Medical and Paediatric Oncology · 09.01.2026
DOI: 10.1055/s-0045-1815709 ↗Auf einen Blick
Bei 30 Patientinnen mit HER2-positivem Mammakarzinom war die pathologische Komplettremission unter TCHP höher als unter TCH. Schwere therapiebedingte Nebenwirkungen wurden nicht beobachtet.
Fragestellung
Vergleich von Dual- und Single-HER2-Blockade im neoadjuvanten Setting bei HER2-positivem Mammakarzinom hinsichtlich pathologischer Komplettremission und Toxizität.
Methode
Single-Center-Studie mit 30 randomisierten Patientinnen; Vergleich von TCHP mit TCH im neoadjuvanten Setting.
Ergebnisse
Pathologische Komplettremission: 66,7 % (6/9; 95 %-KI 29,9–92,5) unter TCHP vs. 15,8 % (3/19; 95 %-KI 3,4–39,6) unter TCH; absolute Differenz 50,9 % (95 %-KI 12,8–74,5).
Schlussfolgerung der Autor:innen
Die Autor:innen schlussfolgern, dass die Zugabe von Pertuzumab im neoadjuvanten Setting bei HER2+ Patientinnen eine wertvolle Strategie ist.
Kernaussagen
- pCR unter TCHP höher als unter TCH
- Keine grad-3- oder höheren therapiebedingten Ereignisse
- 30 randomisierte Patientinnen in einer Single-Center-Studie
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Medical and Paediatric Oncology, erschienen am 09.01.2026. Verfasst von Velappan Arumugam und 1 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Breast cancer remains the leading cause of morbidity and mortality among women and has now become a molecular spectrum rather than a single disease. The human epidermal growth factor receptor 2 (HER2) overexpressing subtype is a rather aggressive form of breast cancer, and its prognosis is improving at a faster pace in recent times with the advent of multiple strategies with targeted agents. In this study, we planned to compare dual and single HER2 blockades—docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) and trastuzumab, docetaxel, and carboplatin (TCH)—in the neoadjuvant setting and compare the pathological complete response rates for each protocol, and to assess the toxic effect profile of the regimens. We enrolled 30 patients randomized in a 1:2 fashion to TCHP (n = 9) and TCH (n = 21). The patients' age, tumor staging, and N staging were well matched. The completion rates of neoadjuvant therapy were 100% in the TCHP arm and 90% in the TCH arm. Breast conservation surgery rates were 22.2 and 5%, respectively, in the TCHP and TCH arms. The pathological complete response rate was 66.7% (6/9; 95% confidence interval [CI]: 29.9–92.5) in the TCHP arm compared with 15.8% (3/19; 95% CI: 3.4–39.6) in the TCH arm, with an absolute difference of 50.9% (95% CI: 12.8–74.5). No grade 3 or higher treatment-related adverse events were observed. With no added grade 3 adverse events documented in the TCHP arm, we concluded that the addition of pertuzumab would serve as a valuable strategy in the HER2+ subset in the neoadjuvant setting in the population of South Indian origin.
Zitieren
APA
Arumugam, V., & Akila, B. (2026). Assessment of Response to Neoadjuvant Chemotherapy with Single and Dual HER2 Blockade in HER2-Positive Breast Cancers: A Single-Center Experience. Indian Journal of Medical and Paediatric Oncology. https://doi.org/10.1055/s-0045-1815709
Vancouver
Arumugam V, Akila B. Assessment of Response to Neoadjuvant Chemotherapy with Single and Dual HER2 Blockade in HER2-Positive Breast Cancers: A Single-Center Experience. Indian Journal of Medical and Paediatric Oncology. 2026. doi:10.1055/s-0045-1815709
BibTeX
@article{Arumugam2026,
author = {Arumugam, Velappan and Akila, Boopathi},
title = {Assessment of Response to Neoadjuvant Chemotherapy with Single and Dual HER2 Blockade in HER2-Positive Breast Cancers: A Single-Center Experience},
journal = {Indian Journal of Medical and Paediatric Oncology},
year = {2026},
doi = {10.1055/s-0045-1815709}
}
EUVIMED